fitc labeled mouse anti human cd21 antibody  (Bio-Rad)

Journal: Vaccine

Article Title: Immunogenicity assay of the Leishmune ® vaccine against canine visceral leishmaniasis in Brazil

doi: 10.1016/j.vaccine.2008.07.029

Figure Lengend Snippet: Lymphocyte phenotypes in peripheral blood mononuclear cells of dogs with visceral leishmaniasis subjected to immunotherapy with Leishmune ®

Article Snippet: At this time, 4 μl of the FITC-labelled mouse anti-human-CD21 (Mouse-IgG1-clone IOB1a) monoclonal antibody (Immunotech Co., Marseille, France) was used in a direct immunofluorescence procedure.

Techniques:

Journal: Vaccine

Article Title: Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine

doi: 10.1016/j.vaccine.2003.11.039

Figure Lengend Snippet: Evolution of anti-FML antibodies and intradermal reaction in infected dogs submitted to immunotherapy (A–D) with the FML-QuilA vaccine. The y -axis represents the FML-ELISA absorbency values of each dog serum (1/100) (A–C) and the thickness of skin test in millimeter (D). Control values of the saline control were subtracted from the DTH reaction due to the Leishmania antigen. Reactions showing diameters ≥5 mm were considered positive. Total antibodies were detected by using peroxidase-labeled protein-A (1:16,000). The cut-off value for IgG is Abs 492 ηm: 0.450. Goat anti-dog IgG1 heavy chain specific (1:2000) or IgG2 (1:32,000) conjugated with horseradish-peroxidase were used for the IgG subtype determination of each serum.

Article Snippet: At this time 2 μl of the FITC-labeled mouse anti-human-CD21 (Mouse-IgG1-clone IOB1a) monoclonal antibody (Immunotech Co. Marseille, France) was used in a direct immunofluorescence procedure.

Techniques: Infection, Enzyme-linked Immunosorbent Assay, Labeling

Journal: Vaccine

Article Title: Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine

doi: 10.1016/j.vaccine.2003.11.039

Figure Lengend Snippet: T cell phenotypes in peripheral blood mononuclear cells of dogs with visceral leishmaniasis submitted to immunotherapy with the FML-vaccine

Article Snippet: At this time 2 μl of the FITC-labeled mouse anti-human-CD21 (Mouse-IgG1-clone IOB1a) monoclonal antibody (Immunotech Co. Marseille, France) was used in a direct immunofluorescence procedure.

Techniques:

Journal: Vaccine

Article Title: Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine

doi: 10.1016/j.vaccine.2003.11.039

Figure Lengend Snippet: Evolution of anti-FML antibodies and intradermal reaction in infected asymptomatic dogs submitted to immunotherapy and the FML-vaccine. Total IgG (A), IgG1 and IgG2 anti-FML antibodies (B) and the intradermal reaction to L. donovani freeze–thawed promastigote lysate (C) of 21 dogs with canine visceral leishmaniasis from an endemic area, treated with three vaccine doses and the first annual booster of the FML-vaccine when FML-seropositive but completely asymptomatic. The results represent the mean and standard deviation. Total IgG (D) and IgG1 and IgG2 anti-FML-antibodies (E) of 45 control dogs, seropositive to FML and asymptomatic, from an endemic area, that did not receive any treatment. All animals were monitored for a 22 months period. The percent of obits due to canine visceral leishmaniasis and of symptomatic cases were recorded until the end of 22 months, both in the vaccinated and in the control group (F).

Article Snippet: At this time 2 μl of the FITC-labeled mouse anti-human-CD21 (Mouse-IgG1-clone IOB1a) monoclonal antibody (Immunotech Co. Marseille, France) was used in a direct immunofluorescence procedure.

Techniques: Infection, Standard Deviation